Merck has found a way forward for its stalled oral antiretroviral islatravir, using a lower, 0.75 mg dose in three newly launched phase 3 trials and in a previously paused phase 2 trial that has been languishing under a clinical hold after patients developed decreases in total lymphocyte and CD4+ T-cells.
Source: Drug Industry Daily